These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9244143)

  • 1. The disposition of valproyl glycinamide and valproyl glycine in rats.
    Blotnik S; Bergman F; Bialer M
    Pharm Res; 1997 Jul; 14(7):873-8. PubMed ID: 9244143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid.
    Bialer M; Kadry B; Abdul-Hai A; Haj-Yehia A; Sterling J; Herzig Y; Shirvan M
    Biopharm Drug Dispos; 1996 Oct; 17(7):565-75. PubMed ID: 8894115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide.
    Hadad S; Bialer M
    Biopharm Drug Dispos; 1997 Oct; 18(7):557-66. PubMed ID: 9330777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine.
    Hadad S; Bialer M
    Pharm Res; 1995 Jun; 12(6):905-10. PubMed ID: 7667199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats.
    Blotnik S; Bergman F; Bialer M
    Drug Metab Dispos; 1996 May; 24(5):560-4. PubMed ID: 8723737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats.
    Blotnik S; Bergman F; Bialer M
    Eur J Pharm Sci; 1998 Apr; 6(2):93-8. PubMed ID: 9795021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The structural requirements for the design of antiepileptic-glycine derivatives.
    Sussan S; Dagan A; Blotnik S; Bialer M
    Epilepsy Res; 1999 Apr; 34(2-3):207-20. PubMed ID: 10210036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives.
    Levi M; Yagen B; Bialer M
    Pharm Res; 1997 Feb; 14(2):213-7. PubMed ID: 9090712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetic and pharmacodynamic analysis of phthaloyl glycine derivatives with potential antiepileptic activity.
    abu Salach O; Hadad S; Haj-Yehia A; Sussan S; Bialer M
    Pharm Res; 1994 Oct; 11(10):1429-34. PubMed ID: 7855047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic analysis and anticonvulsant activity of glycine and glycinamide derivatives.
    Sussan S; Dagan A; Bialer M
    Epilepsy Res; 1999 Jan; 33(1):11-21. PubMed ID: 10022362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs.
    Bialer M
    J Control Release; 1999 Nov; 62(1-2):187-92. PubMed ID: 10518650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide.
    Spiegelstein O; Yagen B; Bialer M
    Epilepsia; 1999 May; 40(5):545-52. PubMed ID: 10386522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide.
    Semba J; Curzon G; Patsalos PN
    Br J Pharmacol; 1993 Apr; 108(4):1117-24. PubMed ID: 8485621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and anticonvulsant activity of three monoesteric prodrugs of valproic acid.
    Badir K; Haj-Yehia A; Vree TB; van der Kleijn E; Bialer M
    Pharm Res; 1991 Jun; 8(6):750-3. PubMed ID: 2062805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of valproic acid.
    Hadad S; Vree TB; van der Kleijn E; Bialer M
    Biopharm Drug Dispos; 1993 Jan; 14(1):51-9. PubMed ID: 8427944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some pharmacological implications of MAO-mediated deamination of branched aliphatic amines: 2-propyl-1-aminopentane and N-(2-propylpentyl)glycinamide as valproic acid precursors.
    Yu PH; Davis BA
    J Neural Transm Suppl; 1990; 32():89-92. PubMed ID: 2128515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide.
    Bialer M; Hadad S; Kadry B; Abdul-Hai A; Haj-Yehia A; Sterling J; Herzig Y; Yagen B
    Pharm Res; 1996 Feb; 13(2):284-9. PubMed ID: 8932450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion of orally administered 2-n.pentylaminoacetamide into glycinamide and glycine in the rat brain.
    Christophe J; Kutzner R; Nguyen-Bui ND; Damien C; Chatelain P; Gillet L
    Life Sci; 1983 Aug; 33(6):533-41. PubMed ID: 6888183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous delivery of valproic acid and glycine to the brain. Deamination of 2-propylpentylglycinamide by monoamine oxidase B.
    Yu PH; Davis BA
    Mol Chem Neuropathol; 1991 Aug; 15(1):37-49. PubMed ID: 1772533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Species difference in the in vitro and in vivo metabolism of amtolmetin guacil.
    Hotha KK; Dasari VB; Shaik AN; Syed M; Shivva V; Lakshmanarao RK; Korlakunta JN; Mullangi R
    Arzneimittelforschung; 2010; 60(11):667-74. PubMed ID: 21175039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.